NervGen Pharma (NervGen Pharma) LT-Debt-to-Total-Asset : 0.00 (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is NervGen Pharma LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. NervGen Pharma's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.00.

NervGen Pharma's long-term debt to total assets ratio declined from Mar. 2023 (0.01) to Mar. 2024 (0.00). It may suggest that NervGen Pharma is progressively becoming less dependent on debt to grow their business.

NervGen Pharma LT-Debt-to-Total-Asset Historical Data

The historical data trend for NervGen Pharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NervGen Pharma LT-Debt-to-Total-Asset Chart

NervGen Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

NervGen Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	0.01	0.01	0.01	-

NervGen Pharma LT-Debt-to-Total-Asset Calculation

NervGen Pharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	0.079	/	9.866
	=

NervGen Pharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	0.061	/	23.482
	=

NervGen Pharma (OTCPK:NGENF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

NervGen Pharma LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of NervGen Pharma's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

NervGen Pharma (NervGen Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (OTCPK:NGENF) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

9UA:Germany NGEN:Canada

Address

2955 Virtual Way, Suite 480, Vancouver, BC, CAN, V5M 4X6

Website

https://www.nervgen.com

NervGen Pharma Corp is a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases. The company is developing drugs for the treatment of spinal cord injury, multiple sclerosis, and Alzheimer's disease. It operates in a single segment, which is the research and development of pharmaceutical drugs.

NervGen Pharma (NervGen Pharma) Headlines

From GuruFocus

NervGen Pharma To Webcast At VirtualInvestorConferences.com July 11th

By PRNewswire PRNewswire • 07-09-2019